Full text is available at the source.
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models
Anti-obesity effects of GIP receptor blockers alone and combined with GLP-1 receptor activators in animal models
AI simplified
Abstract
Administration of anti-GIPR antibodies resulted in reduced body weight gain and improved metabolic parameters in mice and nonhuman primates.
- GIP receptor (GIPR) has been linked to obesity through multiple genetic studies.
- Knockout of GIPR in mice protects against diet-induced obesity.
- A mouse anti-murine GIPR antibody reduced food intake and improved metabolic parameters in diet-induced obesity mice.
- In obese nonhuman primates, an anti-human GIPR antibody led to more pronounced weight loss compared to mice.
- Codosing anti-GIPR antibodies with GLP-1 receptor agonists enhanced weight loss effects in both mice and nonhuman primates.
- GIPR's role in pancreatic β-cells was excluded from influencing body weight regulation.
AI simplified